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External beam radiation therapy for unresectable non-
small cell carcinoma ofthe lung has produced significant 
survival in patients with disease limited to one hemi-
thorax. New approaches to improve the results of 
radiation treatment of these patients include interstitial 
implantation, the use of hypoxic cell sensitizers, biologic 
response modifiers, as well as changes in the technique 
of radiation therapy. This includes the use of modern 
computerized tomographic scanning technology for 
better definition of tumor volume as well as the use of 
two fractions per day in the treatment of non-small cell 
carcinoma of the lung. Initial results of these studies are 
encouraging, with an increase in patient survival 
suggested. 
M ore than 135,000 new cases of bronchogenic 
carcinoma were diagnosed dur ing 1983 in the United 
States, 80% of the non-small cell type (1). Lung cancer is 
the most lethal malignancy affl icting American men, and 
its incidence among women is rising rapidly. Approxi -
mately 117,000 deaths are attr ibuted to this disease 
annually. 
Only a small percentage of patients have resectable non-
small cell lesions at the time of initial diagnosis; of the 
resected patients, only about 50% wi l l survive more than 
five years (2). 
For patients with pathological Stage I disease (Tl NO 
M O , Tl N l M O , or T2 NO M O ) , the out look for survival 
after surgical resection is reasonable. In a large series 
reported by Mounta in (3), 80% were alive at one year and 
55% at five years. Unfortunately, after complet ion of 
surgical staging, fewer than 20% of patients fall into this 
category. Of the 3-5% of patients who have Stage II 
disease (T2 N l M O ) , median survival after surgery is only 
18 months; 20-35% of patients survive for five years, 
depending upon histology. For patients with resectable 
Stage 111 disease, median survival is about one year; 
death f rom local tumor occurs in two thirds of these 
patients (2). 
Radiation Therapy 
The role of radiation therapy in the management of 
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unresectable or inoperable non-small cell carcinoma has 
become better def ined over the years. Roswit, et al (4) 
reported a 22% one-year survival rate for patients treated 
by radiation therapy with 4,000 to 6,000 cGy* in four to six 
weeks, as compared to a 16% one-year survival rate for a 
similar patient group treated wi th a placebo. In a 
randomized trial a group of patients treated with 4,000 
cGy in four weeks by a combinat ion of radiation therapy 
and ni t rogen mustard was compared to a delayed 
treatment group. The one-year survival rate of both 
groups was 24% (5). This percentage is lower than that 
recently reported by the Radiation Therapy Oncology 
Group for inoperable non-small cell cancer (6). Further 
evidence for the effectiveness of radiation therapy in 
control l ing the tumor and prolonging survival is pro-
vided by the studies of Bromley and Szur (7), Bloedorn, 
et al (8), and Heilman, et al (9). These studies revealed 
that doses f rom 4,700 to 6,000 cGy, when used before 
operat ion, were irradiated with complete destruction of 
the primary tumor in 40-60% of the cases. 
Cox, et al, (10) and Eisert, et al (11) described 30% tumor 
clearance in patients treated with lower than 4,500 cGy, 
as compared to 50% with higher doses. Results were 
better wi th daily treatment five times per week rather 
than wi th one to three weekly fractions. Petrovich, et al 
(12), in the Veterans Administration Lung Cancer Study 
Group, related dose and tumor control to survival; 50% 
of patients who received 1,600 rets or more of radiation 
alone survived one year. The use of CCNU and hydroxy-
urea in this randomized study did not influence survival 
or local control. 
•The Gray (Gy) has replaced the rad as a unit of radiat ion dose, 1 Gray = 100 rad, 
1 cGy = 1 rad. 
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Studies of the Radiation Therapy Oncology 
Croup (RTOG) 
Since its inception, the Radiation Therapy Oncology 
Group (RTOG) has carried out studies on the treatment of 
lung cancer. In a prospective tr ial, the RTOG compared 
four different radiation treatment schemes for inoper-
able localized non-small cell lung cancer: 4,000 cGy 
cont inuous, 4,000 cGy split course (two courses of 
treatment interrupted by a treatment-free interval), 
5,000 cGy continuous, and 6,000 cGy split course. Latest 
available data f rom RTOG protocol 73-01 (6,13) indicate 
that the most effective dose fractionation for localized 
unresectable non-small cell lung cancer is 6,000 cGy 
delivered with a daily dose of 200 cGy per fract ion, five 
times weekly. When compared to the other three treat-
ment schemes of the study, a dose response curve can be 
suggested. An analysis of the fractionation schemes 
which use 200 cGy per day five days a week revealed that 
local failure at 4,000 cGy was 64%; at 5,000 cGy, it was 45%; 
and at 6,000 cGy it was 38%. Conversely, the proport ion 
of patients who have not failed either locally or at distant 
sites is 18% at 4,000 cGy, 22% at 5,000 cGy, and 29% at 
6,000 cGy. No distinct dose response relationship is 
evident for distant metastases, which develop in 37% of 
patients treated with 4,000 cGy; at 5,000 cGy, the relation-
ship is 50%, and at 6,000 cGy, 46%. The higher rates for 
the 5,000 cGy and 6,000 cGy levels suggest that because 
of better local control more patients are living longer 
and are more likely to manifest distant metastases. 
Depending upon cell type, between one third and one 
half of patients with squamous, large cell and adenocar-
cinoma of the lung are expected ultimately to develop 
distant metastases. 
Survival after radiation therapy 
Several recent studies have shown that local control by 
radiation therapy achieved significantly longer survival, 
compared to that of patients for whom local control was 
not possible. In a prospective RTOG trial, responding 
patients had significantly longer median survival than 
did non-responding patients (75 versus 36 weeks). The 
median survival for all patients according to the different 
treatment regimens did not differ significantly (37 to 47 
weeks), but the frequency of distant metastases in adeno-
carcinoma and large cell undifferentiated carcinoma was 
twice that observed for patients who had squamous cell 
carcinoma. While prognostic factors include tumor size, 
lymph node involvement, and performance status 
(20,21), the RTOG data suggest that tumor cell type may 
also be an important prognostic factor. The prognosis is 
distinctly better for squamous cell carcinoma than for 
adenocarcinoma or large cell undifferentiated carci-
noma (9,13). 
Complications f rom radiation therapy for non-small cell 
carcinoma must be monitored carefully. Brady, et al (22) 
and Phillips and Margolis (23) determined that radiation 
pneumonit is occurs in approximately 50% of patients 
treated with 2,650 cGy in 20 fractions to the whole lung, 
making it necessary to reduce the volume of the irradi-
ated lung to a min imum. Clinical symptoms are not 
always present despite radiographic changes. These 
sequellae are exaggerated by combined modality treat-
ment which produces an increased reaction to the 
radiation therapy in the lung as well as in other tissues 
such as the esophagus. 
Split course versus continuous irradiation 
The use of daily fractionation as a continuous course 
compared to a split course of irradiation therapy is in 
dispute. In a split course a treatment-free interval is 
spaced between two or more treatment series of moder-
ately high daily doses. Lee (14) and Levitt, et al (15) 
reported no significant advantage for the split course, 
while Holsti and Vuorinen (16) and Abramson and 
Cavanaugh (17) described a one-year survival advantage 
for patients treated with a 4,000 cGy split course as 
opposed to a 6,000 cGy continuous course. Guthr ie, et al 
(18) found that 6,000 cGy in a split course gave a higher 
survival at 12 months than a 4,000 cGy split course, whi le 
Salazar, et al (19) also reported some advantage for a split 
course regimen. The latter authors found, however, that 
survival is not the optimal parameter because the devel-
opment of distant metastatic disease is overwhelming. 
They stressed that local tumor control is the most 
significant result of successful therapy. 
Combination Radiation and Chemotherapy 
Based on the reported effectiveness of radiation and 
chemotherapy in treating other cancers, such combina-
tions have also been tried in lung cancer to minimize 
distant metastases as well as to assure better local 
control . Adjuvant chemotherapy and/or radiotherapy 
have contr ibuted little to improve the excellent results 
in patients whose disease has been totally resected. 
Furthermore, combined modality approaches have been 
ineffective in locally advanced or inoperable disease 
settings (24-28). In addit ion to local-regional extent of 
the disease, failures frequently are due to distant 
metastases. Mohu idd in (29) reported that, at autopsy, 
25% of patients with squamous cell carcinoma and 55% 
of patients with large cell or adenocarcinoma had distant 
metastases. This high frequency of distant metastases 
justifies the cont inued investigation of systemic therapy 
in addit ion to local treatment, realizing the risk of higher 
inc idence of t rea tment - re la ted side effects and 
complications. 
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New Approaches 
Current studies are aimed at improving the results of 
radiation therapy in unresectable non-small cell car-
cinoma. Investigative changes in time-dose fractionation 
schedules include: 1) increasing total doses by one 
fraction per day, and 2) combining a large field treatment 
to the primary tumor and area of potential nodal 
involvement with a smaller boost field treatment l imited 
to lymph nodes and areas grossly involved by the 
primary tumor. Doses of approximately 7,500 cGy, simi-
lar to those presented by Mohu idd in (29), are used in 
these trials. In addit ion, the Radiation Oncology Group 
is complet ing a pilot study in which two fractions per day 
of 1.2 cGy were given 4 to 6 hours apart, for a total of 
5,040 cGy to a large f ield. Subsequently, these are 
increased to 6,000-7,440 cGy with small fields directed to 
tumor bearing areas only. This study requires the use of 
CT scanning and computer ized treatment plans in order 
to minimize irradiation of normal tissues, especially 
lung, heart, and spinal cord. In 91 patients [ including 
those wi th T4 and N3 lesions as well as smaller ones (T2, 
T3, N l , N2)], a one-year survival of 71% has been 
achieved. Complications have been acceptable; only 
one patient developed life-threatening pneumonitis 
from radiation therapy (30). 
Other attempts are being made to improve therapeutic 
results by the use of neutrons. In an RTOG study, 
treatment is randomized to photons alone, neutrons 
alone, or a mixed photon and neutron beam. Approxi-
mately one hundred patients have been studied thus far; 
the results are encouraging but not decisive. 
Attempts have been made to enhance radiation effect 
wi th hypoxic cell sensitizers, especially with misoni-
dazole. A recent RTOG study employed fractionation up 
to 6,000 cGy accompanied by daily administration of 
misonidazole (0.4 mg/m^), but no significant improve-
ment in local control and patient survival has yet been 
reported. In another study, approximately one hundred 
patients are receiving six fractions of radiation of 600 cGy 
twice a week with and wi thout administration of misoni-
dazole (1.75 mg/m2) on the same day; no data are yet 
available. 
In past studies, no advantage was demonstrated in the 
use of the immune modif ier, levamisole, in treating 
unresectable small cell and non-small cell carcinoma. 
Based on the results of a pilot study performed at George-
town University (31), the RTOG has undertaken a study 
to compare the treatment of non-small cell carcinoma of 
the lung by radiation therapy (6,000 cGy photons) with 
and wi thout supplemental administration of thymosin 
(0.9 mg/m2 twice weekly) for one year after the 
complet ion of radiation. 
Studies which combined radiation therapy and chemo-
therapy, such as VP-16 and cis-platnum, have yielded 
variable results. In some studies, response rates have 
reached 56% (32), but an RTOG study of approximately 
20 patients has not produced sufficient data for analysis. 
Other modalities include 1) the combination of external 
beam radiation therapy with administration of immuno-
globulins tagged with radioactive isotopes, and 2) laser 
radiation for relief of obstruction of the bronchial tree in 
combination with radiation therapy. These procedures 
are too recent to be evaluated. 
In summary, radiation therapy can lead to significant 
tumor control as well as to improved survival in patients 
with non-small cell carcinoma, depending on the extent 
of disease at presentation. Radiation alone with tradit ion-
al once-a-day fractionation achieves complete regres-
sion in about 53% of T l lesions and in 35-48% of T3 
lesions. Median survival varies f rom 30 weeks for non-
responders to 75 weeks for complete responders. The 
result is significantiy related to performance status and 
other prognostic factors. Forty percent of complete 
responders survive for two years. New techniques have 
improved the one-year survival rate to 71%. However, 
patients who fail to respond or whose disease progresses 
under treatment have a very brief survival. 
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